Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions

clarithromycin

  • Species Distribution and Macrolide Susceptibility of <em>Mycobacterium fortuitum</em> Complex Clinical Isolates
    Mechanisms of Resistance
    Species Distribution and Macrolide Susceptibility of Mycobacterium fortuitum Complex Clinical Isolates

    The understanding of species distribution and inducible macrolide resistance in the Mycobacterium fortuitum complex (MFC) is limited. Of 90 mostly respiratory MFC clinical isolates, half were M. fortuitum, followed by M. peregrinum...

    Su-Young Kim, Seong Mi Moon, Byung Woo Jhun, O Jung Kwon, Hee Jae Huh, Nam Yong Lee, Seung Heon Lee, Sung Jae Shin, Shannon H. Kasperbauer, Gwen A. Huitt, Charles L. Daley, Won-Jung Koh
  • High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of <span class="named-content genus-species" id="named-content-1">Mycobacterium ulcerans</span> Disease
    Experimental Therapeutics
    High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease

    Buruli ulcer (BU), caused by Mycobacterium ulcerans, is a neglected tropical skin and soft tissue infection that is associated with disability and social stigma. The mainstay of BU treatment is an 8-week course of rifampin (RIF) at 10 mg/kg of body weight and 150 mg/kg streptomycin (STR).

    Till F. Omansen, Deepak Almeida, Paul J. Converse, Si-Yang Li, Jin Lee, Ymkje Stienstra, Tjip van der Werf, Jacques H. Grosset, Eric L. Nuermberger
  • Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of <span class="named-content genus-species" id="named-content-1">Rhodococcus equi</span> from Foals in Central Kentucky, 1995 to 2017
    Epidemiology and Surveillance
    Emergence of Resistance to Macrolides and Rifampin in Clinical Isolates of Rhodococcus equi from Foals in Central Kentucky, 1995 to 2017

    The objective of this study was to determine the prevalence of Rhodococcus equi strains resistant to macrolides and rifampin over time in clinical samples from foals submitted to diagnostic laboratories in central Kentucky. We performed a retrospective observational study of all clinical samples from foals that were submitted to veterinary diagnostic laboratories in...

    Laura Huber, Steeve Giguère, Nathan M. Slovis, Craig N. Carter, Bonnie S. Barr, Noah D. Cohen, Justine Elam, Erdal Erol, Stephan J. Locke, Erica D. Phillips, Jacqueline L. Smith
  • Open Access
    Clinical Therapeutics
    Rifabutin Acts in Synergy and Is Bactericidal with Frontline Mycobacterium abscessus Antibiotics Clarithromycin and Tigecycline, Suggesting a Potent Treatment Combination
    Mark Pryjma, Ján Burian, Charles J. Thompson
  • Susceptibility
    Lipopeptide Paenipeptin Analogues Potentiate Clarithromycin and Rifampin against Carbapenem-Resistant Pathogens
    Sun Hee Moon, En Huang
  • Epidemiology and Surveillance
    Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides
    Einat Gorelik, Reem Masarwa, Amichai Perlman, Victoria Rotshild, Mordechai Muszkat, Ilan Matok
  • Open Access
    Clinical Therapeutics
    The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease
    Qi Guo, Haiqing Chu, Meiping Ye, Zhemin Zhang, Bing Li, Shiyi Yang, Wei Ma, Fangyou Yu
  • Open Access
    Susceptibility
    Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro
    Devika Mukherjee, Mu-Lu Wu, Jeanette W. P. Teo, Thomas Dick
  • Open Access
    Mechanisms of Resistance
    Antagonism between Front-Line Antibiotics Clarithromycin and Amikacin in the Treatment of Mycobacterium abscessus Infections Is Mediated by the whiB7 Gene
    Mark Pryjma, Ján Burian, Kevin Kuchinski, Charles J. Thompson
  • Open Access
    Mechanisms of Resistance
    The Bifunctional Enzyme SpoT Is Involved in the Clarithromycin Tolerance of Helicobacter pylori by Upregulating the Transporters HP0939, HP1017, HP0497, and HP0471
    Xiwen Geng, Wen Li, Zhenghong Chen, Sizhe Gao, Wei Hong, Xiaoran Ge, Guihua Hou, Zhekai Hu, Yabin Zhou, Beini Zeng, Wenjuan Li, Jihui Jia, Yundong Sun

Pages

  • Next
  • 1
  • 2
Back to top

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

Copyright © 2019 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596